

Niki Karachaliou

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3534077/niki-karachaliou-publications-by-citations.pdf>

Version: 2024-04-15

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

4,590
citations

36
h-index

64
g-index

141
ext. papers

5,529
ext. citations

7.7
avg, IF

5.61
L-index

#	Paper	IF	Citations
127	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015 , 47, 250-6	36.3	320
126	Genetics and biomarkers in personalisation of lung cancer treatment. <i>Lancet, The</i> , 2013 , 382, 720-31	40	223
125	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1403-1410	2.2	198
124	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015 , 1, 149-57	13.4	193
123	The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. <i>Clinical Cancer Research</i> , 2014 , 20, 2001-10	12.9	182
122	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. <i>Nature Medicine</i> , 2015 , 21, 1038-47	50.5	177
121	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. <i>Cancer Cell</i> , 2017 , 32, 238-252.e9	24.3	150
120	KRAS mutations in lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 205-14	4.9	149
119	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, 435-444	35.1	133
118	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758834017749748 ⁸	5.4	128
117	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 1066-75	3.3	120
116	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine, the</i> , 2018 , 6, 771-781	35.1	107
115	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 453-74	8.9	106
114	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017 , 116, 802-810	8.7	93
113	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918762094 ⁴	5.4	74
112	Clinical assessment of immune-related adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918764628	5.4	74
111	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758834017745012	5.4	73

110	SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2396-404	12.9	71
109	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. <i>Melanoma Research</i> , 2015 , 25, 486-95	3.3	68
108	Real-time liquid biopsies become a reality in cancer treatment. <i>Annals of Translational Medicine</i> , 2015 , 3, 36	3.2	68
107	Large-scale screening for somatic mutations in lung cancer. <i>Lancet, The</i> , 2016 , 387, 1354-1356	4.0	67
106	Tumor immune microenvironment characterization and response to anti-PD-1 therapy. <i>Cancer Biology and Medicine</i> , 2015 , 12, 74-8	5.2	57
105	Human endogenous retroviruses and cancer. <i>Cancer Biology and Medicine</i> , 2016 , 13, 483-488	5.2	51
104	Lung cancer in 2014: optimizing lung cancer treatment approaches. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 75-6	19.4	48
103	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. <i>EBioMedicine</i> , 2018 , 29, 112-127	8.8	46
102	Identification of , , and Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017 , 63, 751-760	5.5	45
101	Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. <i>Molecular Oncology</i> , 2019 , 13, 2633-2645	7.9	45
100	Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. <i>Translational Lung Cancer Research</i> , 2014 , 3, 70-4	4.4	45
99	The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. <i>Current Oncology Reports</i> , 2018 , 20, 70	6.3	43
98	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1266-1276	8.9	42
97	Lung cancer: Maintenance therapy and precision medicine in NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 549-50	19.4	41
96	Advances in immunotherapy for treatment of lung cancer. <i>Cancer Biology and Medicine</i> , 2015 , 12, 209-225.2	5.2	41
95	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015 , 4, 728-42	4.4	40
94	Liquid Biopsy in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2016 , 3, 69	4.9	40
93	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , 2016 , 5, 2-15	4.4	38

92	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 35-45	3.8	38
91	Comprehensive molecular screening: from the RT-PCR to the RNA-seq. <i>Translational Lung Cancer Research</i> , 2013 , 2, 87-91	4.4	36
90	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. <i>Lung Cancer: Targets and Therapy</i> , 2017 , 8, 109-125	2.9	34
89	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015 , 12, 87-95	5.2	33
88	Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017 , 8, 47305-47316	3.3	32
87	Adaptive resistance to targeted therapies in cancer. <i>Translational Lung Cancer Research</i> , 2013 , 2, 152-9	4.4	32
86	The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2013 , 2, 172-9	4.4	31
85	Mechanisms of resistance to osimertinib. <i>Journal of Thoracic Disease</i> , 2020 , 12, 2851-2858	2.6	30
84	Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPBIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. <i>PLoS ONE</i> , 2013 , 8, e74611	3.7	29
83	Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 401-2	19.4	28
82	Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). <i>EBioMedicine</i> , 2019 , 39, 207-214	8.8	28
81	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. <i>Cancer Research</i> , 2019 , 79, 546-556	10.1	28
80	ALK and ROS1 as a joint target for the treatment of lung cancer: a review. <i>Translational Lung Cancer Research</i> , 2013 , 2, 72-86	4.4	25
79	Targeted drugs in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016 , 5, 51-70	4.4	25
78	HER3 as a Therapeutic Target in Cancer. <i>BioDrugs</i> , 2017 , 31, 63-73	7.9	24
77	Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. <i>Cancers</i> , 2019 , 11,	6.6	24
76	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015 , 4, 721-7	4.4	22
75	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. <i>Cancer Biology and Medicine</i> , 2015 , 12, 79-86	5.2	22

74	Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, 167-177	4.9	20
73	Predicting resistance by selection of signaling pathways. <i>Translational Lung Cancer Research</i> , 2014 , 3, 107-15	4.4	20
72	ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. <i>Translational Lung Cancer Research</i> , 2014 , 3, 122-30	4.4	20
71	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. <i>OncoTargets and Therapy</i> , 2016 , 9, 6361-6376	4.4	20
70	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 2047-2063	4.4	19
69	Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). <i>Targeted Oncology</i> , 2017 , 12, 513-523	5	18
68	Unraveling the genomic complexity of small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016 , 5, 363-6	4.4	18
67	Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1324-1337	8.9	18
66	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , 2017 , 60, 1-11	14.4	17
65	BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 295-300	8.9	17
64	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. <i>Oncotarget</i> , 2016 , 7, 56619-56627	3.3	16
63	Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2013 , 2, 208-21	4.4	16
62	CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. <i>Translational Lung Cancer Research</i> , 2013 , 2, 65-71	4.4	15
61	MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S379-S380 ¹⁴	8.9	14
60	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 1021-1030	3.5	14
59	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 807-15	3.5	14
58	ARID1A Gene Driver Mutations in Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e255-e257	8.9	14
57	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. <i>Melanoma Research</i> , 2018 , 28, 195-203	3.3	13

56	Feasibility of cell-free circulating tumor DNA testing for lung cancer. <i>Biomarkers in Medicine</i> , 2016 , 10, 417-30	2.3	13
55	ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 966-8	35.1	13
54	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 416-425	8.9	13
53	Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. <i>Translational Lung Cancer Research</i> , 2016 , 5, 525-531	4.4	13
52	Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP). <i>Frontiers in Oncology</i> , 2019 , 9, 254	5.3	12
51	Relationship between gene mutation and lung cancer metastasis. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 243-8	9.6	12
50	RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 474-479	5	12
49	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 713-722	5.9	11
48	Targeting PKC/PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. <i>Cell Communication and Signaling</i> , 2019 , 17, 137	7.5	11
47	Possible application of circulating free tumor DNA in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1364-S1372	2.6	11
46	Platelets and their role in cancer evolution and immune system. <i>Translational Lung Cancer Research</i> , 2015 , 4, 713-20	4.4	11
45	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 295-304	4	10
44	Novel molecular targets for the treatment of lung cancer. <i>Current Opinion in Oncology</i> , 2020 , 32, 37-43	4.2	9
43	Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). <i>International Journal of Biological Sciences</i> , 2019 , 15, 2607-2614	11.2	9
42	Activation of viral defense signaling in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918793105	3.4	9
41	Co-mutations in EGFR driven non-small cell lung cancer. <i>EBioMedicine</i> , 2019 , 42, 18-19	8.8	8
40	Using genetics to predict patient response to platinum-based chemotherapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 21-32	1.6	7
39	RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer. <i>Lancet Oncology</i> , 2016 , 17, 1623-1625	21.7	7

38	Trends in immunotherapy for brain metastases. <i>Lancet Oncology, The</i> , 2016 , 17, 859-860	21.7	7
37	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015 , 4, 704-12	4.4	7
36	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 304-310	8.9	7
35	Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitors. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3883-93	3.3	6
34	Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors. <i>Annals of Palliative Medicine</i> , 2013 , 2, 114-7	1.7	6
33	Targeting PKCEPAK1 in EGFR-mutation positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 667-673	4.4	6
32	Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. <i>Translational Lung Cancer Research</i> , 2019 , 8, 340-351	4.4	5
31	Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. <i>Therapeutic Advances in Respiratory Disease</i> , 2020 , 14, 1753466620938553	4.9	5
30	Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives. <i>OncoTargets and Therapy</i> , 2019 , 12, 4567-4575	4.4	5
29	Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. <i>Clinical Lung Cancer</i> , 2011 , 12, 100-5	4.9	5
28	Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. <i>Translational Lung Cancer Research</i> , 2016 , 5, 532-537	4.4	5
27	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.. <i>JCO Precision Oncology</i> , 2021 , 5, 93-102	3.6	5
26	Avelumab in non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2018 , 19, 1423-1424	21.7	5
25	Pharmacogenomics in the treatment of lung cancer: an update. <i>Pharmacogenomics</i> , 2015 , 16, 1751-60	2.6	4
24	Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 1019-1028	3.8	4
23	BRAF and BRAF-inactivating mutations in NSCLC. <i>Lancet Oncology, The</i> , 2017 , 18, 1286-1287	21.7	4
22	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1810-1821	4.4	4
21	Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). <i>Thoracic Cancer</i> , 2019 , 10, 508-518	3.2	3

20	SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations. <i>IScience</i> , 2020 , 23, 101832	6.1	3
19	Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2018 , 19, e126	21.7	3
18	Response to crizotinib in a non-small-cell lung cancer patient harboring an fusion with an atypical insertion. <i>OncoTargets and Therapy</i> , 2018 , 11, 1117-1120	4.4	3
17	Evaluation of Biomarkers for HER3-targeted Therapies in Cancer. <i>EBioMedicine</i> , 2015 , 2, 192-3	8.8	3
16	A critical question for cancer therapy: what new targets exist?. <i>Translational Lung Cancer Research</i> , 2014 , 3, 384-8	4.4	3
15	Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013 , 2, 180-8	4.4	3
14	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018 , 7, 691-702	4.4	3
13	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. <i>Pulmonary Therapy</i> , 2016 , 2, 1-18	3	2
12	Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer. <i>EBioMedicine</i> , 2018 , 33, 16-17	8.8	2
11	Brain metastases in patients with EGFR-mutant non-small-cell lung cancer. <i>Lancet Respiratory Medicine,the</i> , 2017 , 5, 669-671	35.1	2
10	Immune checkpoint blockade (ICB) for first line treatment in non-small cell lung cancer (NSCLC). <i>Translational Cancer Research</i> , 2016 , 5, S408-S410	0.3	2
9	Rhomboids and regulation of receptor tyrosine kinase ligands shedding. <i>EBioMedicine</i> , 2018 , 37, 19-20	8.8	2
8	Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy. <i>EBioMedicine</i> , 2019 , 42, 20-21	8.8	1
7	Small-cell lung cancer: where are we now and what can we expect for the future?. <i>Future Oncology</i> , 2013 , 9, 1065-8	3.6	1
6	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected Mutation-Positive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100084	1.4	1
5	Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study. <i>Translational Lung Cancer Research</i> , 2013 , 2, 58-61	4.4	1
4	Immunotherapy meets targeted therapy: will this team end the war against cancer?. <i>Translational Lung Cancer Research</i> , 2015 , 4, 752-5	4.4	1
3	BRCA1 Expression and Outcome in Patients With -Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100113	1.4	1

- 2 Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma. *Lancet Respiratory Medicine, the*, **2018**, 6, 649-651 35.1 ○
- 1 Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening. *EBioMedicine*, **2015**, 2, 782-3 8.8